AVITA Medical (RCEL) Q2 FY26 earnings call

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

AVITA Medical delivered a strong second quarter, achieving record revenue and raising full-year guidance, driven by robust U.S. Resell adoption and initial traction for CoHelix and Permiaderm. The company is on track to reach cash flow breakeven by Q4 2026, reflecting disciplined commercial execution and operating expense control. Management emphasized the simplification of reimbursement codes for Resell in 2027, which is expected to further support clinical adoption.

You’re reading a preview. Opening the full call uses 1 concall credit.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.